Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmblemHealth Medicare Formulary Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentEmblemHealthPolicy N/A

    EmblemHealth Local 246 Medicare Prescription Drug Formulary (partial)

    Customize your policy alerts

    Sign up for all EmblemHealth policy alerts

    Know when EmblemHealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the plan formulary describing covered prescription drugs, tiers, utilization management (e.g., prior authorization, quantity limits, step therapy), and member services for EmblemHealth Local 246 Medicare prescription drug plan. It affects plan members, prescribing providers, and pharmacies participating with EmblemHealth.

    Policy Summary
    PayerEmblemHealth
    PolicyLocal 246 Medicare Prescription Drug Formulary (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a product's listing includes 'PA' before dispensing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2026-01-01Formulary updated
    AvailableHome delivery
    PA/QL/LA/SPUtilization controls
    877-793-6253Member services
    100+Specialty drugs listed

    Coverage Criteria Overview

    General formulary coverage

    Covered when meeting plan rules and any indicated utilization management requirements

    Formulary coverage general: Drug is listed on the formulary and is subject to its assigned Drug Tier and any Requirements/Limits shown (e.g., PA, QL, LA, SP, ST). Coverage is provided only when the plan's utilization management requirements are met.

    Not all drugs listed are paid by all plans; consult the member's Certificate of Coverage for benefit-specific coverage and cost-sharing.

    Formulary coverage with conditions

    Coverage and utilization controls are product-specific and indicated by tags; coverage is conditional based on meeting PA/LA/QL/SP where listed.

    General rule: When a product entry includes requirement flags, the associated control applies: 'PA' = prior authorization required before coverage; 'QL' = quantity limit; 'LA' = limited availability/authorization; 'SP' = specialty product/distribution or site-of-care restriction.

    Apply the exact Requirements/Limits shown on the specific product line.

    Policy Summary
    PayerEmblemHealth
    PolicyLocal 246 Medicare Prescription Drug Formulary (partial)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2026
    Last ReviewJan 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization when a product's listing includes 'PA' before dispensing.
    SourceLink
    On This Page
    Coverage Criteria OverviewFormulary Coding and Drug ListingsProvider Requirements and Authorization NotesInitial Therapy and Authorization ExamplesStep Therapy IndicatorsQuantity Limits (QL) by ProductSpecialty Pharmacy and Site-of-Care NotesPolicy BackgroundKey Terms and AbbreviationsBiosimilar Products

    Formulary coverage with product-specific utilization controls

    Coverage and utilization controls are product-specific as listed below; coverage is subject to prior authorization, quantity limits, step therapy, limited access, and specialty distribution where annotated.

    Formulary listing rules: Each listed product includes Drug Tier and may include one or more Requirements/Limits (PA, QL, LA, SP, ST). Coverage requires adherence to those per-product controls.

    See individual product entries (Requirements/Limits column) for exact PA, QL, LA, SP, and ST values.

    Formulary coverage with authorization and limits

    Coverage and restrictions as indicated on formulary entries

    Formulary tiers and requirements: Drugs are listed with Drug Tier (e.g., Tier 1 or Tier 2) and may include requirement flags: PA (prior authorization), QL (quantity limit), LA (limited access), SP (specialty). Products with these flags require the corresponding authorization or are subject to limits as shown.

    Providers must follow payer prior authorization processes and adhere to listed quantity limits and site-of-care designations.

    Coverage conditional on listed requirements

    Coverage entries are provided per drug with any additional requirement flags; coverage is conditional on meeting listed PA/QL/LA/SP requirements where indicated.

    Formulary coverage conditional: A drug is covered only when prescribed consistent with its formulary line — including Drug Tier and any Requirements/Limits on the same line (e.g., PA, QL, LA, SP).

    Providers must request and obtain PA or meet QL/LA/SP requirements as shown for each product.

    Per-product utilization controls

    Coverage and utilization controls are defined per product and apply when the product is prescribed for outpatient use.

    Per-product controls: Coverage varies by product; controls may include drug tier assignment, prior authorization (PA), quantity limits (QL), limited access (LA), step therapy (ST), and specialty pharmacy/site-of-care (SP).

    Follow the exact per-product Requirements/Limits (e.g., QL values, PA/LA/SP flags) listed on the formulary line.

    Utilization Management Overview

    Coverage and utilization management as listed (PA and/or QL required for specified products).

    PA and QL requirements overview: Many specialty biologics, certain extended-release or abuse-deterrent opioids, and migraine biologics require prior authorization and have specified quantity limits as listed in the Requirements/Limits column.see individual QL entries

    This formulary excerpt provides administrative flags and quantity values; consult the plan's PA criteria for clinical documentation requirements.

    This formulary excerpt is a plan-level drug list and does not guarantee payment for every listed product. Not all drugs in the list are paid for by all drug benefit plans; members and providers must check the member's Certificate of Coverage or benefit summary to confirm coverage, cost-sharing, and any plan-specific restrictions. For questions about a member's drug benefits, contact the phone number on the member ID card or the member portal.

    The extracted formulary lines show administrative requirement flags (for example, PA = prior authorization; QL = quantity limit; LA = limited access; SP = specialty). This window does not include explicit clinical determinations that label specific indications as medically necessary or not medically necessary — it only lists products with their associated utilization controls and limits. Apply the per-product requirement flags shown on each drug line when seeking coverage.

    Within the provided excerpt there are no explicit medical exclusion statements identifying drugs or indications as categorically not covered for medical necessity reasons. The content is limited to product listings, tiers, and administrative controls; refer to the full plan documents for any formal exclusion language.

    No explicit exclusion statements appear in this segment. Individual entries may note no coverage restrictions or may be designated OTC (for example, fluticasone propionate nasal suspension — Requirements/Limits = OTC), but the excerpt does not provide comprehensive exclusion rules.

    No specific exclusions are stated in the cited chunks. The material focuses on drug listings, tiers, and utilization controls rather than explicit exclusionary policy statements.

    Formulary Coding and Drug Listings

    Formulary drug strength listings (partial)NDCCovered
    NDC/strength listings (partial)Examples listed: amoxicillin (trihydrate) chew tab 125 mg, 250 mg; cap 250 mg, 500 mg; susp 125 mg/5ml, 200 mg/5ml, 250 mg/5ml, 400 mg/5ml; tab 500 mg, 875 mg; amoxicillin & k clavulanate susp 200-28.5 mg/5ml, 250-62.5 mg/5ml, 400-57 mg/5ml; Augmentin ES-600 susp 600-42.9 mg/5ml; amoxicillin & k clavulanate tab 250-125 mg, 500-125 mg, 875-125 mg.
    Listed drug items (no procedure or billing codes in this segment)mixed
    No codes listed
    Antiretrovirals and selected antiviralsmixed
    lamivudine tab 300 mg (Epivir)Drug line as listed
    lamivudine tab 300 mg (Epivir) (alternate line)Listed with QL (30 tablets/30 days)
    lamivudine-zidovudine tab 150-300 mgQL (60 tablets/30 days)
    LIVTENCITY - maribavir tab 200 mgQL (120 tablets/30 days), SP
    lopinavir-ritonavir tab 100-25 mg (Kaletra)QL (180 tablets/30 days)
    maraviroc tab 150 mg (Selzentry)QL (60 tablets/30 days)
    Oral antiviral combosmixed
    ODEFSEY - emtricitabine-rilpivirine-tenofovir af tab 200-25-25 mgQL (30 tablets/30 days)
    PAXLOVID - nirmatrelvir & ritonavir packMultiple pack sizes with QL (11-20 tablets/30 days)
    Antivirals with PA/QLmixed
    PEGASYS - peginterferon alfa-2aPA, SP
    PREVYMIS - letermovir tab 240 mg, 480 mgQL (200 tablets/365 days)
    HIV agents and boostersmixed
    REYATAZ - atazanavir sulfate oral powder packet 50 mgQL (240 packets/30 days)
    ritonavir tab 100 mg (Norvir)QL (360 tablets/30 days)
    STRIBILD - elvitegrav-cobic-emtricitab-tenofovdf tab 150-150-200-300 mgQL (30 tablets/30 days)
    TIVICAY - dolutegravir sodium tab 50 mgQL (60 tablets/30 days)
    Antiparasitics and miscellaneous anti-infectivesmixed
    ANTIMALARIALS groupMultiple entries (e.g., atovaquone-proguanil (Malarone), chloroquine, hydroxychloroquine)
    SOLOSEC - secnidazole granules packet 2 gmListed without limits
    linezolid for susp 100 mg/5ml (Zyvox)Requirements/Limits = PA
    nitazoxanide tab 500 mgQL (12 tablets/90 days)
    Vaccinesmixed
    VACCINES groupMany vaccines listed with Drug Tier = 2; individual entries include ABRYSVO, AREXVY, COMIRNATY (2025-26), GARDASIL 9, SHINGRIX, SPIKEVAX, etc.
    Formulary drug entries with stated limits/flagsmixed
    XTANDI - enzalutamide tab 80 mglisted with QL (60 tablets/30 days), LA, PA, SP
    YONSA - abiraterone acetate micronized tab 125 mglisted with QL (120 tablets/30 days), LA, PA, SP
    ZEJULA - niraparib tosylate tab 100 mg/200 mg/300 mglisted with QL (30 tablets/30 days), PA, SP
    ZELBORAF - vemurafenib tab 240 mglisted with QL (240 tablets/30 days), PA, SP
    ZYDELIG - idelalisib tab 100 mg, 150 mglisted with QL (60 tablets/30 days), PA, SP
    ZYKADIA - ceritinib tab 150 mglisted with QL (90 tablets/30 days), PA, SP
    MOUNJARO - tirzepatide soln auto-injector (various strengths)PA, QL (4 pens/28 days or 4 pens/180 days depending on strength)
    OZEMPIC - semaglutide soln pen-inj (various strengths)PA, QL (1 pen/28 days or 3 pens/28 days depending on strength)
    RYBELSUS - semaglutide tab (3 mg, 7 mg, 14 mg)PA, QL (30 tablets/180 days for 3 mg; 30 tablets/30 days for 7/14 mg)
    JANUVIA - sitagliptin phosphate tab 25/50/100 mgQL (30 tablets/30 days)
    1–10 of 15
    1/2
    Listed products (no procedure codes provided)mixed
    N/AThis chunk contains drug names and strength forms; no CPT/HCPCS/ICD codes provided.
    Formulary entries without billing codesmixed
    NDC/HCPCS not listedNo explicit billing codes provided in this segment; only drug names, strengths, tiers, and requirement flags are present.
    Psychostimulant and related agents (examples from section)mixed
    clonidine hcl tab er 12hr 0.1 mglisted drug presentation
    dexmethylphenidate hcl cap er 24 hr 5 mg - 40 mgFocalin XR presentations
    dexmethylphenidate hcl tab 2.5 mg - 10 mgFocalin tablets
    dextroamphetamine sulfate cap er 24hr 5 mg - 15 mgER dextroamphetamine presentations
    dextroamphetamine sulfate oral solution 5 mg/5mlliquid formulation
    Neurologic and specialty neurology agentsmixed
    AUSTEDO - deutetrabenazine 6 mg, 9 mg, 12 mgtardive dyskinesia therapy
    AVONEX - interferon beta-1a 30 mcg/0.5mlMS disease-modifying therapy
    INGREZZA - valbenazine 40 mg, 60 mg, 80 mgtardive dyskinesia therapy
    GILENYA - fingolimod 0.25 mg, 0.5 mgMS therapy
    Analgesics and narcotic analgesicsmixed
    butalbital-acetaminophen 50-325 mgcombination analgesic
    acetaminophen w/ codeine 300-15 mg, 300-30 mgnarcotic analgesic combinations
    BELBUCA - buprenorphine buccal film 75 mcg - 900 mcgopioid analgesic/maintenance therapy
    Formulary product entries (partial list)mixed
    aspirin chew tab 81 mgOTC
    butalbital-acetaminophen tab 50-325 mgQL (180 tablets/30 days)
    BELBUCA - buprenorphine hcl buccal film various strengthsPA, QL (60 films/30 days)
    fentanyl td patch 72hr 12-100 mcg/hrPA, QL (15 patches/30 days)
    hydrocodone-acetaminophen tab/soln various strengthsQL (various)
    morphine sulfate formulations (tabs, ER, soln)PA for some ER forms, QL (various)
    NUCYNTA ER - tapentadol hcl ER 50-250 mgPA, QL (60 tablets/30 days)
    XTAMPZA ER - oxycodone ER abuse-deterrent capsPA, QL (60-240 capsules/30 days depending on strength)
    ADALIMUMAB (multiple biosimilars and formulations)PA, QL (1-2 pens/syringes per period), SP
    ENBREL - etanercept formulationsPA, QL (4 syringes/28 days), SP
    1–10 of 20
    1/2
    Formulary drug lines (partial)mixed
    rizatriptan benzoate tab 10 mgrizatriptan benzoate tab 10 mg (Maxalt)
    sumatriptan nasal spray 5 mg/act, 20 mg/actsumatriptan nasal spray 5 mg/act, 20 mg/act
    sumatriptan succinate inj 6 mg/0.5mlsumatriptan succinate inj 6 mg/0.5ml
    sumatriptan succinate solution auto-injector 4 mg/0.5ml, 6 mg/0.5mlsumatriptan succinate solution auto-injector (Imitrex statdose sys)
    sumatriptan succinate tab 25 mg, 50 mg, 100 mgsumatriptan succinate tab (Imitrex)
    UBRELVY - ubrogepant tab 50 mg, 100 mgUBRELVY - ubrogepant
    zolmitriptan tab 2.5 mg, 5 mgzolmitriptan
    allopurinol tab 100 mg, 300 mgallopurinol
    colchicine tab 0.6 mgcolchicine
    probenecid tab 500 mgprobenecid
    1–10 of 46
    1/5
    Example quantity limits
    Examples of tablet QLs60 tablets/30 days; 120 tablets/30 days; 360 tablets/30 days; 12 tablets/90 days; 200 tablets/365 days
    ContextQuantity limits vary by product and formulation; see individual drug lines for exact QL and time period
    Use on claimsDispense/claim must match the listed QL for the product (unit and days) to avoid denial
    Quantity limits examples
    Example QL set60 tablets/30 days; 120 tablets/30 days; 4 pens/28 days; 6 pens/30 days
    Typical productsIncludes tablets and multi-dose pens (e.g., GLP‑1 and other injectables) with pen-based QLs
    Action for providersObtain prior authorization when 'PA' is indicated and ensure dispensed quantity adheres to QL
    Insulin quantity limit
    Insulin volume limit100 mls/30 days
    Applies toMultiple rapid-acting, short-acting, and basal insulin presentations (e.g., HUMALOG, NOVOLOG, FIASP, LYUMJEV)
    Denial riskRequests exceeding 100 mls/30 days may be denied per formulary limits
    Tablet quantity limits (examples)
    Tablet QL examples30 tablets/30 days or 60 tablets/30 days depending on product
    Where shownCommon for oral therapies such as GLP‑1 tablets, DPP‑4 agents, and other oral formulations
    Provider noteCheck the product line for the exact tablet QL before dispensing
    Quantity limits examples
    Mixed QL examplesQL (1200 mls/30 days); QL (6 syringes/28 days); QL (60 tablets/30 days); QL (240 capsules/30 days)
    Formats coveredmL (liquid/solution), syringes, tablets, capsules — limits depend on formulation and pack size
    ImplementationEnsure claims reflect both unit type and time window shown in QL to avoid denial
    Quantity Limits examples (exact line values)
    Exact QL examples from linesADVAIR HFA QL 1 inhaler/30 days; AIRSUPRA QL 3 inhalers/30 days; ALYFTREK QL 84 tablets/28 days
    Actionable noteUse the exact per-product QL shown on the formulary line when processing or requesting PA
    ReasonClaims exceeding these stated QLs or lacking PA where required may be denied

    Provider Requirements and Authorization Notes

    Prior Authorization

    Prior Authorization and Utilization Controls

    Prior authorization (PA) and other utilization controls apply to many drugs listed in this formulary. When a drug is annotated with PA, LA (limited access), QL (quantity limit), SP (specialty), or ST (step therapy), prescribers and pharmacies must obtain the required approvals and submit supporting documentation prior to dispensing. Failure to obtain required authorizations or to follow site-of-service/specialty pharmacy routing may result in denial of coverage or claim payment.

    • PA = Prior Authorization — plan requires approval before fill; lack of PA may cause noncoverage.
    • LA = Limited Availability — product may be restricted to certain pharmacies or sites of service.
    • SP = Specialty — may require dispensing via the plan’s specialty pharmacy and additional monitoring.
    • QL = Quantity Limit — plan limits the amount covered per time period; claims exceeding QL may be denied.
    • ST = Step Therapy — some drugs require trials of preferred agents first; ST is indicated where applicable (e.g., select CNS and specialty agents).
    Documentation Required

    Interpretation of Requirement Codes and How to Comply

    Interpretation of requirement codes: PA, LA, QL, SP, and ST indicate utilization management controls. Providers must review these flags on the drug listing and follow the plan’s operational rules when submitting prescriptions and claims.

    • Confirm the specific code(s) shown next to each drug on the formulary entry prior to prescribing.
    • When PA is indicated, submit a prior authorization request and include all required clinical documentation.
    • For LA/SP drugs, follow the plan’s specialty pharmacy or site-of-service requirements.
    • Match the requested quantity on the claim to the stated QL to avoid denial.
    Prior Authorization

    Long‑Acting and Specialty Product Authorization (including SUNLENCA/YEZTUGO)

    Certain long-acting and specialty products (for example, lenacapavir products SUNLENCA/YEZTUGO and other LA/SP agents) require additional handling: limited authorization (LA), prior authorization (PA), specialty pharmacy (SP), and specific quantity limitations. These products commonly have low annual or per‑period QL values and may be limited to specialty dispensing only.

    • SUNLENCA / YEZTUGO (lenacapavir) — flagged LA, QL (annual limits shown), SP; prior authorization required before coverage.
    • Long-acting agents and injectables labeled LA/SP often require documentation of clinical rationale and may be dispensed only through network specialty pharmacies.
    • Claims for LA/SP products submitted without the required PA and correct site-of-service may be denied.
    Documentation Required

    Required Documentation and Claim Matching

    Documentation expectations: when PA, LA, QL, or SP is indicated, providers must submit supporting clinical documentation with the authorization request and ensure claim-level data match the approved authorization (drug, strength, days’ supply, quantity).

    • Include diagnosis, relevant prior treatments (for ST where applicable), and clinical rationale demonstrating medical necessity.
    • For LA/SP drugs, provide site-of-care information and any required monitoring plans.
    • Ensure the NDC/pack size and quantity on the claim match the PA/QL parameters (mismatch can trigger denial).
    • Formulation-specific documentation (e.g., oral solutions, suspensions, injectables) may be required for certain products.
    Denial Risk

    Denial Risk for Unmet Utilization Controls

    Denial risk and enforcement: claims that do not meet utilization controls (missing PA, exceeded QL, incorrect site-of-service, or unmet ST requirements) are at risk for denial. Prior authorization approval must be obtained and in effect at the time of dispensing.

    • Requests exceeding stated QLs (examples in formulary: many insulins, oral solids, and specialty injectables) may be denied.
    • Failure to follow ST where indicated (e.g., certain CNS and specialty agents) may result in noncoverage.
    • Specialty/LA/PA requirements are strictly enforced for many oncology, biologic, and rare-disease therapies; confirm PA and specialty routing before dispensing.
    Note

    Provider Operational Steps and Member Resources

    Operational notes and provider actions: check member’s Certificate of Coverage and contact Customer Service for plan‑specific rules, request forms, or help with reasonable modifications and language assistance. Use the plan’s PA submission process and specialty pharmacy channels as required.

    • Members and providers should verify coverage and cost-sharing via the member portal or ID‑card phone number prior to initiating therapy.
    • If assistance is needed (language access, disability accommodations), contact Customer Service at the number on the member ID card.
    • Follow the payer’s PA form instructions and include all requested supportive documentation to avoid delays.
    Step Therapy

    Step Therapy (ST) — Presence and Documentation

    Step therapy (ST): where ST is indicated on the formulary, the plan may require trial and failure of specified first‑line agents before approving non‑preferred drugs. Some entries in the formulary indicate ST; where ST is not shown, no explicit step requirement is provided in that listing — always verify for the specific product.

    • When ST is shown (drug annotated with ST), document prior trials and outcomes as part of the PA.
    • If ST is not specified in the formulary excerpt, do not assume there are no step requirements — confirm via the PA policy or member plan documents.
    • Examples: KERENDIA and selected CNS agents show ST notation; other agents may require step therapy per plan rules.

    Initial Therapy and Authorization Examples

    Prior authorization for specialty agents

    Examples of products requiring authorization before initiation

    Specialty/initiation: Selected specialty or high-cost agents are subject to prior authorization at initiation (examples in the formulary include biologics and specialty injectables such as certolizumab, vedolizumab, adalimumab products, and certain endocrine/somatic therapies).

    See the product line Requirements/Limits for PA/LA/SP and required QL (e.g., MYALEPT = LA, PA, SP; PEGASYS = PA, SP).

    GLP‑1 and related agents: Certain GLP‑1 receptor agonists and related agents (e.g., RYBELSUS, MOUNJARO, OZEMPIC) are listed with PA and/or QL and require prior authorization per the formulary listing.

    Refer to each product's Requirements/Limits entry for exact PA and QL values.

    Long‑acting/LA products: Long‑acting or limited‑access agents (e.g., SUNLENCA/lenacapavir packs) are designated LA and SP and require authorization prior to initiation.

    Claims lacking required LA/PA/SP authorization may be denied.

    Step Therapy Indicators

    StatementNotes
    Step therapy (ST) may be requiredFormulary indicates ST with the initials 'ST' after drug names; this denotes that preferred therapies must be tried before the listed product will be covered.
    ExamplesSee individual drug lines for ST notation; where 'ST' appears the plan may require trial of preferred agents prior to coverage.
    ObservationImplication
    Step details (specific sequences) not provided in this excerptSome drugs are flagged with PA, QL, LA, or SP indicating utilization management steps are required, but explicit step-therapy sequences are not shown here.
    Management flags presentWhen PA/QL/LA/SP are present, providers must follow those controls; consult full policy for any step-therapy algorithms.
    ProductStep therapy status
    PAXLOVID (nirmatrelvir + ritonavir packs)No explicit step-therapy sequence listed in this window; QL and tier information provided (QL 11–20 tablets/30 days).
    FlagMeaning / Provider action
    PA (Prior Authorization)Indicates prior authorization is required before the plan will cover the drug; obtain approval per payer procedures.
    Other flags (QL, LA, SP)Quantity limits (QL), limited access (LA), and specialty (SP) modify coverage and may require additional authorization or specialty dispensing.
    ObservationInterpretation
    ST flags are not extensively detailed in this excerptPA and QL flags are present for agents commonly subject to step edits (e.g., selected GLP‑1 agonists, tirzepatide, semaglutide), suggesting step edits may apply though explicit step sequences are not shown here.
    DrugStep therapy status
    KERENDIA (finerenone) 10 mg, 20 mgListed with 'ST' indicating step therapy is required; also has QL (30 tablets/30 days).
    DrugST notation
    KERENDIA (finerenone)Requirements/Limits include QL (30 tablets/30 days) and 'ST' — step therapy applies as noted on the drug line.
    SummaryCoverage control
    General remarkNo explicit step therapy sequences are listed in this portion of the formulary; prior authorization (PA), limited access (LA), quantity limits (QL), and specialty (SP) are the primary management controls shown.
    Flags presentStep therapy detail
    PA / LA / QL / SP flags visible on many linesThis segment shows these utilization-management flags but does not specify step-therapy sequences; presence of PA/LA/SP implies additional authorization steps may be required.
    DrugStep therapy notation
    AUVELITY (dextromethorphan HBr–bupropion)Annotated with 'ST' and QL (60 tablets/30 days), indicating a step‑therapy requirement may apply prior to coverage.
    Drugs / FormulationsStep therapy note
    FETZIMA (levomilnacipran), FLUOXETINE DR (90 mg DR), TRINTELLIX (vortioxetine)These branded antidepressant entries include 'ST' in their Requirements/Limits, indicating step therapy is required for specified formulations.
    Antipsychotic / specialty oral formulationsST status
    CAPLYTA (lumateperone), REXULTI (brexpiprazole), RISPERIDONE ODT, VRAYLARListed with QL and some entries include 'ST' (step therapy) indicating step edits apply to select antipsychotics and specialty oral forms.
    Gabapentin / related productsStep therapy flag
    Selected gabapentin and related formulations (e.g., GRALISE, HORIZANT)Some entries are designated 'ST', indicating trial of preferred agents may be required prior to coverage for these products.
    Overall observationPrimary control
    Step therapy sequences not shownIn many parts of the excerpt PA is the predominant management control; explicit ST sequences are often omitted from this window and must be checked on individual product lines or full policy.
    Formulations noted (examples)Implication regarding ST
    Trokendi XR and some ER formulations are listed with PA and QLThese PA/QL designations may imply that step edits are applied in practice, though explicit step-therapy logic is not provided in the excerpt.

    Quantity Limits (QL) by Product

    Examples across section
    Section-wide examplesQL 30 tablets/30 days; QL 60 tablets/30 days; QL 120 tablets/30 days; QL in mL for solutions (varies by product)
    VariationQuantity limits vary by product, pack, and strength — consult the specific drug entry for exact values
    Member guidanceMembers should consult their Certificate of Coverage; PA/QL/LA/SP flags affect coverage and dispensing
    Arikayce
    Arikayce QL28 vials/28 days
    RequirementsListed with LA, PA, QL and SP — may require specialty dispensing and prior authorization
    Source lineSee amikacin (ARIKAYCE) formulary entry for exact pack and limits
    Livtencity (maribavir)
    LIVTENCITY (maribavir) QL120 tablets/30 days
    FlagsListed with LA and SP in addition to QL — prior authorization/limited access and specialty handling apply
    Provider actionObtain PA and ensure quantity matches QL on claim
    lamivudine-zidovudine tab 150-300 mg
    Lamivudine‑zidovudine tab 150‑300 mg QL60 tablets (per listed entry)
    ContextListed under antiretrovirals with a 60‑tablet limit on the formulary line
    Processing noteDispense/claim should reflect the 60‑tablet QL to align with formulary limits
    maribavir tab 200 mg (LIVTENCITY)
    Maribavir (LIVTENCITY) QL120 tablets/30 days
    Formulary flagsListed with LA and SP; requires prior authorization and specialty handling as shown
    Claim requirementEnsure QL matches the product line when submitting claims or PA requests
    ODEFSEY — emtricitabine‑rilpivirine‑tenofovir AF
    ODEFSEY QL30 tablets/30 days
    ProductEmtricitabine‑rilpivirine‑tenofovir AF tablet 200‑25‑25 mg
    Processing noteObserve QL when dispensing; specialty or PA flags may also apply per line
    PREVYMIS — letermovir
    PREVYMIS QL200 tablets/365 days
    Formulation noteAlso listed with pellet pack QL (800 packets/365 days) for alternative presentation
    Coverage notePA/QL/LA flags on line should be followed for authorization and claims
    SUNLENCA therapy packs and tablets
    SUNLENCA therapy packs/tablets QL4–5 tablets/365 days (therapy packs listed with 4 or 5 tablets)
    FlagsDesignated LA and SP — limited authorization and specialty dispensing apply
    Provider actionSubmit required documentation supporting LA/PA and requested quantity
    REYATAZ packet
    REYATAZ packet QL240 packets/30 days
    ProductAtazanavir powder packet 50 mg listed with QL on formulary line
    ActionConfirm packet QL on claim to avoid exceedance denial
    nitazoxanide tab 500 mg
    Nitazoxanide 500 mg QL12 tablets (per listed entry)
    Time window90 days as shown on line (QL 12 tablets/90 days)
    Provider noteVerify days-per-period when dispensing (90‑day window for this product)
    abiraterone acetate
    Abiraterone acetate (250 mg) QL120 tablets/30 days
    FlagsRequires PA and is marked SP on the formulary line
    Use on claimSubmit PA and match the 120‑tablet QL to avoid denial
    encorafenib cap 75 mg (BRAFTOVI)
    BRAFTOVI (encorafenib cap 75 mg) QL180 capsules/30 days
    FlagsListed with LA, PA and SP — limited access, prior authorization and specialty handling apply
    Processing noteAdhere to QL and obtain PA where required
    cabozantinib (CABOMETYX)
    CABOMETYX QL30 tablets/30 days
    FlagsListed with LA, PA, QL and SP — specialty/limited access and PA apply
    Provider actionEnsure dispensing matches 30 tablets/30 days per formulary line
    KOSELUGO — selumetinib
    KOSELUGO QL420 capsules/30 days (per listed line variations)
    FlagsKOSELUGO entries include LA, PA, QL and SP — specialty management applies
    Claim guidanceFollow LA/PA/QL requirements on the line when requesting coverage
    LENVIMA therapy pack examples
    LENVIMA therapy pack QLs14 mg pack: 60 capsules/30 days; 18 mg pack: 90 capsules/30 days; 4 mg pack: 30 capsules/30 days
    FlagsAll therapy packs listed with LA, PA, QL and SP where shown
    Provider noteConfirm correct therapy‑pack QL based on daily‑dose pack referenced on the formulary line
    LENVIMA 18 MG DAILY DOSE therapy pack
    LENVIMA 18 mg pack QL90 capsules/30 days
    ContextListed as LA/PA/QL and SP — specialty handling and prior authorization apply
    ActionUse the pack‑specific QL when processing claims or PA requests
    LENVIMA 4 MG
    LENVIMA 4 mg QL30 capsules/30 days
    Formulary notePack‑specific QLs vary by daily dose — confirm product line
    Provider reminderMatch QL and days on claim to avoid exceedance denials
    LORBRENA 25 mg
    LORBRENA 25 mg QL120 tablets/30 days
    Formulary flagsListed with LA, PA, QL and SP — authorization and specialty handling apply
    Operational noteEnsure claims reflect the 120‑tablet limit for this strength
    LUMAKRAS 120 mg
    LUMAKRAS 120 mg QL240 tablets/30 days
    FlagsListed with LA, PA, QL and SP — limited access and PA apply
    Provider actionSubmit PA and adhere to the 240‑tablet QL on the formulary line
    ROZLYTREK pellet pack 50 mg
    ROZLYTREK pellet pack QL336 packets/28 days
    Product formPellet pack presentation noted with high packet QL
    Processing noteConfirm packet QL when dispensing to align with formulary limits
    TAFINLAR oral suspension 10 mg
    TAFINLAR oral suspension QL840 tablets/28 days
    FlagsListed with PA and SP in addition to QL — follow PA process where required
    Claim guidanceUse the specified 28‑day QL when submitting refill or PA requests
    TUKYSA 50 mg
    TUKYSA 50 mg QL300 tablets/30 days
    FlagsListed with LA, PA, QL and SP — specialty distribution and authorization required
    Provider noteEnsure PA and QL compliance for claims processing
    VITRAKVI oral solution
    VITRAKVI oral solution QL300 mls/30 days
    FormulationsOral solution and capsule presentations have separate QLs listed on formulary lines
    ActionMatch mL QL on dispense/claim for solution presentations
    XTANDI — enzalutamide
    XTANDI QL60 (tablets)/30 days
    FlagsListed with LA, PA, QL and SP — prior authorization and specialty handling apply
    Provider actionObtain PA where indicated and ensure the 60‑tablet limit is reflected on claims
    YONSA — abiraterone acetate micronized
    YONSA QL120 (tablets)/30 days
    Formulary flagsListed with LA, PA, QL and SP — follow PA and specialty dispensing as noted
    Claim guidanceMatch QL exactly on authorization and claim submissions
    ZEJULA — niraparib
    ZEJULA QL30 (tablets)/30 days
    FlagsListed with LA, PA, QL and SP — authorization and specialty handling apply
    Provider noteEnsure PA and QL are adhered to when dispensing
    ZELBORAF — vemurafenib
    ZELBORAF QL240 (tablets)/30 days
    Formulary flagsListed with LA, PA, QL and SP — follow PA procedures as required
    Processing noteUse the 240‑tablet QL on claims for this strength

    Specialty Pharmacy and Site-of-Care Notes

    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Policy Background

    This formulary lists covered drugs (brand and generic), Drug Tier assignments, and utilization management controls (for example, PA, QL, LA, SP) for the EmblemHealth Local 246 Medicare prescription drug plan. Members are advised that generics are preferred when available and that plan-specific coverage and cost-sharing are described in the member's Certificate of Coverage; home delivery and member support resources are available via the member portal or the Customer Service number on the ID card.

    Key Terms and Abbreviations

    Generic drug
    Generic drug definitionA lower-cost equivalent of a brand-name drug; typically dispensed by pharmacists when available unless prescriber requests brand.
    Practical implicationIf patient or prescriber requests brand, pharmacist may dispense brand but member may incur additional cost
    ReferenceSee formulary Definitions section for generic drug guidance
    Abbreviations (PA, QL, ST, SP, OTC, LA, FF)
    PAPrior Authorization
    QLQuantity Limit
    STStep Therapy
    SPSpecialty Drugs / Specialty Pharmacy
    LALimited Availability / Limited Access
    OTCOver The Counter
    Key requirement codes (PA / QL / LA / SP)
    PAPrior Authorization — plan requires approval before coverage; indicated by 'PA' next to product lines
    QLQuantity Limit — maximum quantity allowed per specified time period (e.g., 60 tablets/30 days)
    LALimited Access — product may be limited to specific sites or distribution channels
    SPSpecialty — product designated for specialty pharmacy handling or site-of-service requirements
    Prior Authorization (PA)
    PA (short)Prior Authorization — PA indicates the drug requires approval before coverage is provided
    When shownPA appears adjacent to products that require submission of prior authorization documentation
    ConsequenceFailure to obtain required PA may result in the plan not covering the drug
    Quantity Limit (QL)
    QL (short)Quantity Limit — maximum quantity allowed per time period as specified (e.g., 100 mls/30 days for many insulins)
    ExampleInsulin products commonly show QL (100 mls/30 days)
    Operational noteClaims exceeding listed QL may be denied per formulary limits
    PA / LA / SP definitions
    PA/LA/SP interpretationPA = prior authorization required; LA = limited authorization/limited access; SP = specialty pharmacy or specialty site-of-service
    ImplicationEntries with these flags require adherence to utilization management and possibly specialty dispensing
    Provider actionFollow payer instructions for PA and specialty dispensing when these flags are present
    QL — Quantity limit (definition)
    Quantity Limit (definition)Maximum quantity allowed per time period (e.g., QL (60 tablets/30 days)).
    PurposeUsed to limit covered amounts for a drug over a specified window to align with clinical use and safety
    EnforcementClaims exceeding QL or lacking required PA may be denied
    PA / LA / SP — shorthand explanation
    PA/LA/SP shorthandPA = prior authorization required; LA = limited access/limited authorization; SP = specialty pharmacy/site-of-care designation
    UseThese shorthand flags are shown next to product entries to indicate required controls
    Check product lineConsult the specific formulary line for exact requirements and QL values

    Biosimilar Products

    Note